Patents by Inventor Robert F. Todd, III

Robert F. Todd, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
    Patent number: 4935234
    Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: June 19, 1990
    Assignee: Dana-Farber Cancer Institute
    Inventors: Robert F. Todd, III, Paul J. Simpson, Benedict R. Lucchesi, Stuart F. Scholossman, James D. Griffin
  • Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
    Patent number: 4840793
    Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
    Type: Grant
    Filed: June 11, 1987
    Date of Patent: June 20, 1989
    Assignees: Dana-Farber Cancer Institute, The University of Michigan
    Inventors: Robert F. Todd, III, Benedict R. Lucchesi, Paul J. Simpson, James D. Griffin, Stuart F. Schlossman